Jon Jessmer
Geschäftsführer bei Curapath & Expansion of Drug Delivery Capabilities & Services
Profil
Jon Jessmer currently works as a Vice President of Operations at Curapath & Expansion of Drug Delivery Capabilities & Services.
Aktive Positionen von Jon Jessmer
| Unternehmen | Position | Beginn |
|---|---|---|
Curapath & Expansion of Drug Delivery Capabilities & Services
 Curapath & Expansion of Drug Delivery Capabilities & Services BiotechnologyHealth Technology Curapath & Expansion of Drug Delivery Capabilities & Services is a GMP-grade manufacturer of polyamino-acid (PAA) based nanoparticle encapsulation technology for advanced drug delivery applications. The company is based in Valencia, Spain. The Spanish company offers contract development and manufacturing services, including preclinical development, analytical characterization, technology transfer, GMP manufacturing, and fill/finish services. The company was founded by Benjumea Isabela Del Alcazar, Maria Jesus VicentDocon. Robert Shaw has been the CEO of the company since 2021. | Geschäftsführer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Curapath & Expansion of Drug Delivery Capabilities & Services
Curapath & Expansion of Drug Delivery Capabilities & Services BiotechnologyHealth Technology Curapath & Expansion of Drug Delivery Capabilities & Services is a GMP-grade manufacturer of polyamino-acid (PAA) based nanoparticle encapsulation technology for advanced drug delivery applications. The company is based in Valencia, Spain. The Spanish company offers contract development and manufacturing services, including preclinical development, analytical characterization, technology transfer, GMP manufacturing, and fill/finish services. The company was founded by Benjumea Isabela Del Alcazar, Maria Jesus VicentDocon. Robert Shaw has been the CEO of the company since 2021. | Health Technology |